Faculty profile
David Cherney
Back to facultyThis profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Empagliflozin in Patients with Chronic Kidney Disease.
The New England journal of medicine · 2023
Latest funding
- $2,300,300
Cardiovascular and Renal Protection with SGLT Inhibition in Kidney Transplant Recipients" ('RENAISSANCE') Study
CIHR · 2026 · Principal investigator
1 publications.
Empagliflozin in Patients with Chronic Kidney Disease.
The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R
Cardiovascular and Renal Protection with SGLT Inhibition in Kidney Transplant Recipients" ('RENAISSANCE') Study
Principal investigators: Srinivasan Sridhar, Vikas; Cherney, David Z; Gill, John S; Matas, Arthur J; Mottl, Amy K; Sawinski, Deirdre; Singh, Sunita K
Keywords: Cardiovascular Disease; Chronic Kidney Disease; Heart Failure; Kidney Transplantation; Sglt Inhibition
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Medicine/Nephrology
- Nephrology
Co-authors at University of British Columbia, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.